Skip to main content

Table 2 Number of programs that provide information on each checklist question

From: Public reporting on pharmaceutical industry-led access programs: alignment with the WHO medicine programs evaluation checklist

WHO checklist

Total

Percent (N = 20)

Alignment with countries’ national health and development plans, needs, capacity, laws and policies

7.86

39.29%

The program serves a public health need.

20

100%

The policy objective is clear.

20

100%

The program aligns with health strategic plans and the general development agenda.

10

50%

The program is suitable for the existing infrastructure, capacity, environment and local context.

4

20%

Additional government resources (infrastructure, human resources or funding) that are required have been identified and are available.

0

0%

The program does not divert resources away from other public health priorities.

0

0%

The program has been compared to other approaches/programs/ programmes and has been found to be the most suitable.

1

5%

Strong mechanisms to ensure financial, performance, and public accountability

10.75

53.75%

Roles and responsibilities for all stakeholders involved are clear.

7

35%

The mechanisms for how the program will be carried out are clear.

19

95%

Those responsible for overseeing and monitoring the program have been identified.

10

50%

The process for monitoring and evaluation has been established.

4

20%

Allocation, disbursement and utilization of financial resources have been defined.

7

35%

Performance targets, outputs and results are defined.

19

95%

There is sufficient support for the program amongst political parties, unions, and civil society organizations.

0

0%

Measures to disclose information to the public, including procurement information, contractual obligations, evaluation criteria, progress reports, fund flows, commitments and timelines have been established.

20

100%

Strong risk management and mitigation strategies

0.75

3.75%

Risks have been identified.

1

5%

Mitigation strategies for each risk, have been developed.

1

5%

Due diligence on industry partner has been conducted (including financial, managerial and implementation capacity assessments).

1

5%

Potential conflicts of interest have been identified.

0

0%

Clear transitioning plans for long-term sustainability

6

30%

The program is or will be integrated into the health system.

7

35%

A clear transition plan for when the program ends has been developed.

0

0%

A strategy to ensure sustainability of health gains has been developed.

11

55%